GSK: Back in the Dock

Deny, disavow and disagree.

Last week, we told you about GSK's woes, how crime paid, and how they celebrated their latest win in the Zantac litigation.

Despite celebrating a legal victory in the Zantac litigation, GSK's triumph was short-lived. A Delaware judge allowed 70,000 lawsuits against GSK to proceed to trial. 

The decision, based on expert testimony linking the drug to cancer, caused GSK's share price to plummet by 9%, resulting in an $8.9 billion loss in market value.

In response, GSK rapidly reaffirmed its position, prioritising remaining resolute. Sending a message to the media and investors only—disregarding public opinion and two old geezers at TTE just won't cut it.

GSK intends to fight all cases and is already appealing the Delaware ruling. Their strategy is to prevent the evidence from ever reaching the courtroom door. 

Judge Vivian Medinilla's ruling deemed scientific evidence presented by lawyers in over 70,000 cases admissible. This allowed scientists to testify about the link between the plaintiff…